SARS-CoV-2-mediated inflammatory response in lungs: should we look at RAGE?
作者信息
Rojas Armando, Gonzalez Ileana, Morales Miguel A
机构信息
Biomedical Research Laboratories, Medicine Faculty, Catholic University of Maule, Talca, Chile.
Molecular and Clinical Pharmacology Program, Institute of Biomedical Sciences, University of Chile, Santiago, Chile.
出版信息
Inflamm Res. 2020 Jul;69(7):641-643. doi: 10.1007/s00011-020-01353-x. Epub 2020 May 5.
Abstract
摘要
相似文献
1
SARS-CoV-2-mediated inflammatory response in lungs: should we look at RAGE?严重急性呼吸综合征冠状病毒2介导的肺部炎症反应：我们应该关注晚期糖基化终末产物受体吗？
Inflamm Res. 2020 Jul;69(7):641-643. doi: 10.1007/s00011-020-01353-x. Epub 2020 May 5.
2
COVID-19: gastrointestinal symptoms and potential sources of SARS-CoV-2 transmission.新型冠状病毒肺炎：胃肠道症状及严重急性呼吸综合征冠状病毒2的潜在传播源
Anaesthesiol Intensive Ther. 2020;52(2):171-172. doi: 10.5114/ait.2020.93867.
3
Impaired Breakdown of Bradykinin and Its Metabolites as a Possible Cause for Pulmonary Edema in COVID-19 Infection.缓激肽及其代谢产物分解受损可能是新冠病毒感染导致肺水肿的原因
Semin Thromb Hemost. 2020 Oct;46(7):835-837. doi: 10.1055/s-0040-1712960. Epub 2020 Jun 11.
4
Single-cell RNA sequencing data suggest a role for angiotensin-converting enzyme 2 in kidney impairment in patients infected with 2019-novel coronavirus.单细胞RNA测序数据表明，血管紧张素转换酶2在感染2019新型冠状病毒的患者肾脏损伤中发挥作用。
Chin Med J (Engl). 2020 May 5;133(9):1129-1131. doi: 10.1097/CM9.0000000000000783.
5
Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体阻滞剂对无高血压的新冠患者有益吗？
Pharmacol Res. 2020 Sep;159:104959. doi: 10.1016/j.phrs.2020.104959. Epub 2020 Jun 4.
6
Safety considerations for neuraxial anaesthesia in parturients with COVID-19.新型冠状病毒肺炎产妇椎管内麻醉的安全考量
Br J Anaesth. 2020 Sep;125(3):e313-e314. doi: 10.1016/j.bja.2020.05.005. Epub 2020 May 14.
7
[ACE2 and coronavirus - a question of balance and dynamics?].[血管紧张素转换酶2与冠状病毒——平衡与动态变化的问题？]
Lakartidningen. 2020 Apr 17;117:F3S3.
8
COVID-19 and the Heart.新型冠状病毒肺炎与心脏
Arq Bras Cardiol. 2020 Apr;114(4):598-600. doi: 10.36660/abc.20200209. Epub 2020 Mar 30.
9
Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?2019冠状病毒病（COVID-19）：血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂是否具有双相效应？
J Am Heart Assoc. 2020 Apr 7;9(7):e016509. doi: 10.1161/JAHA.120.016509. Epub 2020 Apr 1.
10
Pain: A potential new label of COVID-19.疼痛：新冠病毒疾病的一个潜在新标识。
Brain Behav Immun. 2020 Jul;87:159-160. doi: 10.1016/j.bbi.2020.05.025. Epub 2020 May 7.
引用本文的文献
1
Role of the renin-angiotensin system in the development of COVID-19-associated neurological manifestations.肾素-血管紧张素系统在新型冠状病毒肺炎相关神经表现发展中的作用。
Front Cell Neurosci. 2022 Sep 16;16:977039. doi: 10.3389/fncel.2022.977039. eCollection 2022.
2
The Remarkable Roles of the Receptor for Advanced Glycation End Products (RAGE) and Its Soluble Isoforms in COVID-19: The Importance of RAGE Pathway in the Lung Injuries.晚期糖基化终末产物受体（RAGE）及其可溶性异构体在新型冠状病毒肺炎（COVID-19）中的显著作用：RAGE信号通路在肺损伤中的重要性
Indian J Clin Biochem. 2023 Apr;38(2):159-171. doi: 10.1007/s12291-022-01081-5. Epub 2022 Aug 18.
3
RAGE against the Machine: Can Increasing Our Understanding of RAGE Help Us to Battle SARS-CoV-2 Infection in Pregnancy?与 RAGE 作斗争：提高对 RAGE 的认识能否帮助我们对抗妊娠合并 SARS-CoV-2 感染？
Int J Mol Sci. 2022 Jun 7;23(12):6359. doi: 10.3390/ijms23126359.
4
Mechanical control of innate immune responses against viral infection revealed in a human lung alveolus chip.在人类肺泡芯片中揭示的针对病毒感染的固有免疫反应的机械控制。
Nat Commun. 2022 Apr 8;13(1):1928. doi: 10.1038/s41467-022-29562-4.
5
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Management of Mild-to-Moderate Symptomatic COVID-19.抗氧化和抗炎药理学方法在管理轻至中度有症状 COVID-19 中的潜在作用综述。
Med Sci Monit. 2022 Mar 8;28:e936292. doi: 10.12659/MSM.936292.
6
Impairing RAGE signaling promotes survival and limits disease pathogenesis following SARS-CoV-2 infection in mice.抑制 RAGE 信号通路可促进感染 SARS-CoV-2 的小鼠的存活并限制疾病发病机制。
JCI Insight. 2022 Jan 25;7(2):e155896. doi: 10.1172/jci.insight.155896.
7
COVID-19, the Pandemic of the Century and Its Impact on Cardiovascular Diseases.2019冠状病毒病，世纪大流行及其对心血管疾病的影响。
Cardiol Discov. 2021 Nov 22;1(4):233-258. doi: 10.1097/CD9.0000000000000038. eCollection 2021 Dec.
8
Large Screening Identifies ACE2 Positively Correlates With NF-κB Signaling Activity and Targeting NF-κB Signaling Drugs Suppress ACE2 Levels.大规模筛查发现血管紧张素转换酶2（ACE2）与核因子κB（NF-κB）信号活性呈正相关，靶向NF-κB信号通路的药物可降低ACE2水平。
Front Pharmacol. 2021 Nov 19;12:771555. doi: 10.3389/fphar.2021.771555. eCollection 2021.
9
Cytokine storm in the pathophysiology of COVID-19: Possible functional disturbances of miRNAs.COVID-19 病理生理学中的细胞因子风暴：miRNAs 可能出现的功能紊乱。
Int Immunopharmacol. 2021 Dec;101(Pt A):108172. doi: 10.1016/j.intimp.2021.108172. Epub 2021 Sep 21.
10
Common contributing factors to COVID-19 and inflammatory bowel disease.新冠病毒病和炎症性肠病的常见共同促成因素。
Toxicol Rep. 2021;8:1616-1637. doi: 10.1016/j.toxrep.2021.08.007. Epub 2021 Aug 31.
本文引用的文献
1
Response by Zhang et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19".张等人对关于文章《住院使用血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂与 COVID-19 住院高血压患者死亡率的关联》的信件的回复
Circ Res. 2020 Jun 5;126(12):e142-e143. doi: 10.1161/CIRCRESAHA.120.317242. Epub 2020 Jun 4.
2
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）进入细胞依赖于 ACE2 和 TMPRSS2，可被一种临床验证的蛋白酶抑制剂所阻断。
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
3
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges.严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）和 2019 年冠状病毒病（COVID-19）：疫情和挑战。
Int J Antimicrob Agents. 2020 Mar;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924. Epub 2020 Feb 17.
4
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
5
AGE-RAGE Stress in the Pathophysiology of Pulmonary Hypertension and its Treatment.衰老受体晚期糖基化终末产物应激在肺动脉高压病理生理学及其治疗中的作用
Int J Angiol. 2019 Jun;28(2):71-79. doi: 10.1055/s-0039-1687818. Epub 2019 Apr 19.
6
Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis.AGE-R 介导血管紧张素诱导的炎症和动脉粥样硬化形成。
J Clin Invest. 2019 Jan 2;129(1):406-421. doi: 10.1172/JCI99987. Epub 2018 Dec 10.
7
Crucial role of RAGE in inappropriate increase of smooth muscle cells from patients with pulmonary arterial hypertension.晚期糖基化终末产物受体（RAGE）在肺动脉高压患者平滑肌细胞异常增殖中的关键作用。
PLoS One. 2018 Sep 4;13(9):e0203046. doi: 10.1371/journal.pone.0203046. eCollection 2018.
8
Inhibition of RAGE Axis Signaling: A Pharmacological Challenge.抑制 RAGE 轴信号：药理学挑战。
Curr Drug Targets. 2019;20(3):340-346. doi: 10.2174/1389450119666180820105956.
9
COPD as an endothelial disorder: endothelial injury linking lesions in the lungs and other organs? (2017 Grover Conference Series).慢性阻塞性肺疾病作为一种内皮功能紊乱疾病：肺部与其他器官病变之间的内皮损伤联系？（2017年格罗弗会议系列）
Pulm Circ. 2018 Jan-Mar;8(1):2045894018758528. doi: 10.1177/2045894018758528.
10
All the "RAGE" in lung disease: The receptor for advanced glycation endproducts (RAGE) is a major mediator of pulmonary inflammatory responses.肺部疾病中的所有“愤怒”：晚期糖基化终产物受体（RAGE）是肺部炎症反应的主要介质。
Paediatr Respir Rev. 2017 Jun;23:40-49. doi: 10.1016/j.prrv.2017.03.012. Epub 2017 Mar 18.
Zotero 插件